BofA lowered the firm’s price target on CG Oncology (CGON) to $60 from $62 as the firm pushes back launch timing for creto to 2027 and updates ...

The Colors Festival, under the artistic direction of Farid Rueda, is in its final days until November 2, 2025. And it is under the theme of Halloween, and more specifically Dia de los Muertos, that ...

En Córdoba, siendo las diez horas del día 20 de marzo de dos mil veinticinco, se reúnen los señores y señoras relacionados al margen, miembros de la Comisión Paritaria del Convenio Colectivo de del ...

Piper Sandler launched coverage for a few biotech companies in the oncology space, as mentioned below: CG Oncology (NASDAQ:CGON) rated Overweight with a $55 price target: "Investor expectations for ...

Ralph A. Matteo passed away peacefully on July 29, 2025 at the age of 83. Born and raised in Middletown, Connecticut, he was the son of State Senator Michael Matteo and Angeline (Cello) Matteo, whose ...

CHESHIRE — Students gathered under the setting sun on the high school's football field at Thursday's ceremony to celebrate the Class of 2025. The graduation ceremony included speeches, selfies, cheers ...

CGON’s presence at the American Urological Association (AUA) conference in late April 2025 highlighted Creto’s potential as a best-in-class treatment for NMIBC. The company presented data that ...

El Boletín Oficial del Estado (BOE) y el Diario Oficial de Galicia (DOG) publican este lunes el real de creto de transferencia de las competencias sobre el litoral a Galicia, que serán ejercidas de ...

The Overweight rating by Cantor Fitzgerald indicates the firm’s confidence in CG Oncology’s stock performance potential, backed by the anticipated success of creto in the oncology market. The $75.00 ...

Tradicionalmente se viene autorizando el ejercicio de actividades musicales y artísticas en los espacios y terrenos públicos mediante Decreto emanado de la Consejería de Servicios Públicos de este ...

Cretostimogene grenadenorepvec showed a 75.5% complete response rate in high-risk BCG-unresponsive NMIBC patients, with durable responses at 12 and 24 months. The treatment was well-tolerated, with ...